Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with prophylactic platelet transfusions with standard‐dose schedule (moderate certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with standard‐dose schedule (low certainty).
1 finding from 1 review